January 28, 2014
LAKEWOOD, Colo.--January 28, 2014--The FDA recently cleared the PMN protocol for clinical use on the Terumo BCT Spectra Optia system . With this availability, clinicians now have the ability to perform PMN collections with greater choice and flexibility to customize each procedure. This news follows recent Terumo BCT announcements regarding FDA clearance of the red blood cell exchange (RBCX) protocol and therapeutic plasma exchange (TPE) with single-needle access on the Spectra Optia system.
The FDA clearance was received following a premarket notification file review which included U.S. PMN clinical trial data.
"Terumo BCT is pleased to have received clearance for the PMN procedure on the Spectra Optia system--which we believe will benefit patients and clinicians across the U.S. As the very latest protocol cleared by FDA for patient care on the next-generation Spectra Optia system, we are thrilled to now give caregivers an even broader range of options for advancing therapeutic apheresis and cell collections using the Spectra Optia system."
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.